bioRxiv Science⌕ Search

bioRxiv · 10.1101/2025.07.31.666261

B7-H4 Binds Galectin-9 Glycosylation-Dependently and Attenuates Galectin-9-Mediated CD28/AKT Activation and T Cell Death

Abstract

B7-H4, a member of the B7 family, is broadly expressed on various cancer cells and has been implicated in negative immune regulation, particularly in suppressing anti-tumor immunity. However, the receptor for B7-H4 and the molecular mechanisms underlying its immunoinhibitory effects remain poorly understood. In this study, using peritoneal immune cells from mice adoptively transferred with OVA-expressing tumor cells and OVA-specific OT-1 T cells, we identified Galectin-9 (Gal-9) as a binding partner for B7-H4 and elucidated its role in modulating T cell responses through this interaction. We demonstrated that glycosylation in the IgC domain of B7-H4 is required for its binding to Gal-9; while the N-terminal carbohydrate recognition domain (N-CRD) of Gal-9, including the R65 residue in the N-CRD, is essential for this interaction. Additionally, we found that other B7 family members (B7.1, B7.2, B7-H2, and B7-DC) and immune cell surface receptors (CD28, 2B4, CD226, and SLAMF1) also bind to Gal-9 at comparable levels to B7-H4 and T cell immunoglobulin mucin receptor 3 (TIM-3). In vitro functional assays revealed that B7-H4 inhibits Gal-9-induced activation of CD28 downstream signaling and reduces Gal-9-mediated T cell death. In vivo, Gal-9 deficiency in mice resulted in a significant reduction in the proportion of splenic CD4+ T cells, whereas B7-H4 deficiency exhibited no observable phenotype. Furthermore, B7-H4 and Gal-9 double-knockout mice displayed no additional phenotype differences compared to Gal-9 single-knockout mice. Notably, tumor growth following tumor cell challenge was unaffected in all three knockout models (Gal-9 single-, B7-H4 single-, or double-knockout). Collectively, these findings suggest that B7-H4, other B7 family members, Gal-9, and T cell surface immune receptors form a complex regulatory network that modulates T cell activity and anti-tumor responses, although no single member exerts a major effect. This study provides a detailed molecular characterization of the interaction between B7-H4 and Gal-9 and identifies other previously unknown Gal-9 binding partners, offering valuable insights into the intricate regulatory network involving these molecules.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Wang, R. Z., Yang, F., SUI, J.. 2025-08-01. B7-H4 Binds Galectin-9 Glycosylation-Dependently and Attenuates Galectin-9-Mediated CD28/AKT Activation and T Cell Death. https://doi.org/10.1101/2025.07.31.666261

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Ksp37 is a rapidly mobilized NK cell secretory protein that engages FGF2

A key feature of natural killer (NK) cells is their preloaded arsenal of effector molecules, allowing them to rapidly respond upon activation. In this study, we characterized a previously unexplored secretory protein, termed killer-specific secretory protein of 37 kDa (Ksp37), which is highly abundant in differentiated CD56dim NK cells. Ksp37 is rapidly secreted in a dose-dependent and JAK-1 dependent manner upon low levels of cytokine stimulation, making it a sensitive readout for NK cell activation. Following secretion, intracellular levels were rapidly replenished, preserving responsiveness to subsequent cytokine stimulation. We found that Ksp37 is stored in polarized intracellular compartments distinct from those containing canonical cytotoxic effector molecules, including granzyme B and perforin, which require stronger stimulation for release. Lastly, we identified Ksp37 as a novel binding partner of fibroblast growth factor 2 (FGF2). This opens new avenues of exploration for the role of NK cells in remodeling their extracellular environment by modulating the FGF2-FGFR1 axis, which plays a key role in tumor growth, angiogenesis and tissue repair.

immunology↗

ACE-engineered human iPSC-derived neutrophils enhance host defense against multidrug-resistant bacterial infections

Severe neutropenia predisposes patients to life-threatening infections, while donor-dependent granulocyte transfusions are limited by availability and variable cell quality. Here, we engineered human induced pluripotent stem cells (iPSCs) to constitutively or inducibly express angiotensin-converting enzyme (ACE) and differentiated them into functional ACE-engineered neutrophils (ACE-iNeu). ACE expression enhanced granulocytic maturation, reactive oxygen species generation, inflammatory cytokine production, and antimicrobial signaling. ACE-iNeu exhibited enhanced bactericidal activity against methicillin-resistant Staphylococcus aureus and multidrug-resistant Pseudomonas aeruginosa. Following adoptive transfer into neutropenic mice, ACE-iNeu significantly reduced circulating and tissue bacterial burdens. Integrated metabolomic and transcriptomic analyses revealed ACE-associated alterations in adenine nucleotide abundance and developmental and inflammatory pathways. Together, these findings establish ACE engineering as a strategy to enhance the production and antimicrobial function of human iPSC-derived neutrophils and support further preclinical development of engineered granulocyte therapies for severe drug-resistant infections.

immunology↗

Tetravalent dengue mRNA vaccination orchestrates balanced four-serotype immunity with durable memory and protection in mice.

An effective dengue vaccine must establish durable immunity across four dengue virus (DENV) serotypes, evade antibody-dependent enhancement (ADE), and overcome immune imprinting from prior exposure. Here, we developed TetprM-E mRNA-LNP, a tetravalent vaccine comprising LNP-formulated nucleoside-modified mRNAs encoding DENV1-4 precursor membrane-envelope (prM-E) antigens, and evaluated its immunogenicity, durability, protection and breath across serotype-specific immune backgrounds. Three immunization strategies elicited neutralizing titers greater than 1:1500 against each serotype. Passive transfer of immune sera conferred 100% survival and reduced viremia after lethal DENV2 challenge in immunocompromised mice. Vaccination induced DENV envelope (env)-specific CD8+T cells and CD4-dependent germinal-center responses. DENV env-binding antibodies persisted for 34 weeks alongside DENV env-specific memory B cells. Vaccine-elicited sera showed no measurable in vitro ADE. Although monovalent priming initially biased antibody responses, TetprM-E mRNA-LNP vaccination broadened neutralization across DENV1-4 regardless of priming serotype. Together, TetprM-E mRNA-LNP elicits broad, durable, and protective immunity despite serologic constraints from pre-existing immunity.

immunology↗